Survival analysis showed that patients with low NUSAP1 levels exhibited improved PFS in NSCLC) and OS in kidney cancer and SKCM when treated with anti-PD-1/PD-L1 therapy, compared to those with high NUSAP1 levels (Figure 7E and Supplementary Figure S6). This evidence concerns the gene NUSAP1 and non-small cell lung carcinoma.